Outcome Measures and Treatment Endpoints other Than Platelet Count in Childhood Idiopathic Thrombocytopenic Purpura

ABSTRACT

Therapy for children with acute idiopathic thrombocytopenic purpura (ITP) has been controversial, in great part because it is not evidence based. Some physicians are activists, treaters, or interventionists with regard to therapy of ITP whereas others have been described as nontreaters or noninterventionists. Platelet count (which is often extremely low in ITP) has generally been employed as a surrogate measure of hemorrhagic risk even though life-threatening or fatal bleeding is rare. Virtually all of the randomized clinical trials conducted in childhood ITP have focused on platelet counts as the sole outcome measure. However, other determinants should influence clinical decision making, including assessment of bleeding tendency. Laboratory testing has not been helpful in this regard, but clinical assessment by means of semiquantitative bleeding scores may prove more useful than simply designating a patient as having a ``dry'' or ``wet'' purpura. The side effects as well as costs (direct and indirect) of therapy must also be considered when attempting to weigh the merits of drug therapy against their risks. Finally, the effect of ITP and its treatment on health-related quality of life should be determined. Measurement tools to assess each of these alternative outcome measures are in early stages of development. Employing them in addition to platelet counts in future clinical trials will allow treatment to be based more on scientific data than treatment philosophy.

KEYWORD

Thrombocytopenia - idiopathic thrombocytopenic purpura - ITP - platelets - bleeding

REFERENCES

• 1 Lilleyman V S. Definitions and dogma in childhood idiopathic thrombocytopenic purpura.  Pediatr Hematol Oncol . 1993;  10 11-14
• 2 Lilleyman V S. Management of childhood idiopathic thrombocytopenic purpura.  Br J Haematol . 1999;  105 871-875
• 3 Buchanan G R. ITP: how much treatment is enough?.  Contemp Pediatr . 2000;  17 112-121
• 4 Bolton-Maggs P HB. Idiopathic thrombocytopenic purpura.  Arch Dis Child . 2000;  83 220-222
• 5 Vesely S, Buchanan G R, Cohen A, Raskob G, George J. Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: results of a survey of practicing pediatric hematology/oncology specialists.  J Pediatr Hematol Oncol . 2000;  22 55-61
• 6 George J N, Woolf S H, Raskob G E. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology.  Blood . 1996;  88 3-40
• 7 Bolton-Maggs P HB, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines.  Lancet . 1997;  350 620-623
• 8 Chessels J. Chronic idiopathic thrombocytopenic purpura: primum non nocere.  Arch Dis Child . 1989;  64 1326-1328
• 9 Buchanan G R. Overview of ITP treatment modalities in children.  Blut . 1989;  59 96-104
• 10 Buchanan G R. The nontreatment of childhood idiopathic thrombocytopenic purpura.  Eur J Pediatr . 1987;  146 107-112
• 11 Dickerhoff R, von Ruecker A. The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment.  J Pediatr . 2000;  137 629-632
• 12 George J N. Initial management of immune thrombocytopenic purpura in children: is supportive counseling without therapeutic intervention sufficient?.  J Pediatr . 2000;  137 598-600
• 13 Medeiros D, Buchanan G R. Current controversies in the management of idiopathic thrombocytopenic purpura during childhood.  Pediatr Clin North Am . 1996;  43 757-772
• 14 Lilleyman J S. Intracranial hemorrhage in idiopathic thrombocytopenic purpura.  Arch Dis Child . 1994;  71 251-253
• 15 Woerner S J, Abildgaard C F, French B N. Intracranial hemorrhage in children with idiopathic thrombocytopenic purpura.  Pediatrics . 1981;  67 453-460
• 16 Rosthøj S, Hedlund-Treutiger J, Rajantie I, Zeller B. Nordic study of risks associated with idiopathic thrombocytopenic purpura: Preliminary results (Abst).  Nord Med 2000 . 25
• 17 Sutor A H, Harms A. Prospektive Umfrage über die akute Immunthrombozytopenie (ITP) im Kindesalter in Deutschland (ESPED-Studie)(Abst).  Monatsschr Kinderheilkd 1998.
• 18 Medeiros D, Buchanan G R. Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome.  J Pediatr . 1998;  133 334-339
• 19 Eden O B, Lilleyman J S. Guidelines for management of idiopathic thrombocytopenic purpura.  Arch Dis Child . 1992;  67 1056-1058
• 20 Dubansky A S, Oski F A. Controversies in the management of acute idiopathic thrombocytopenic purpura: a survey of specialists.  Pediatrics . 1986;  77 49-52
• 21 Cripe T P. Idiopathic thrombocytopenic purpura: reasons to resolve the chaos.  J Pediatr Hematol Oncol . 1999;  21 465-466
• 22 Imbach P, Berchtold W, Hirt A. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood.  Lancet . 1985;  2 464-468
• 23 Rosthøj S, Nielsen S, Pedersen F K, and The Danish ITP Group. Randomized trial comparing intravenous immunoglobulin with methylprednisolone pulse therapy in acute idiopathic thrombocytopenic purpura.  Acta Paediatr . 1996;  85 910-915
• 24 Blanchette V S, Luke B, Andrew M. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura.  J Pediatr . 1993;  123 989-995
• 25 Blanchette V S, Imbach P, Andrew M. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura.  Lancet . 1994;  344 703-707
• 26 Tarantino M D, Madden R M, Fennewald D L, Patel C C, Bertolone S J. Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin.  J Pediatr . 1999;  134 21-26
• 27 Zunich K M, Harkonen W S, Woloski M, Kingsbury L. Intravenous anti-D immunoglobulin for childhood acute immune thrombocytopenic purpura.  Lancet . 1995;  346 1363-1365
• 28 Modak S I, Bussel J B. Treatment of children with immune thrombocytopenic purpura: are we closer to resolving the dilemma?.  J Pediatr . 1998;  133 313-314
• 29 Harker L A, Slichter S J. The bleeding time as a screening test for evaluation of platelet function.  N Engl J Med . 1972;  287 155-159
• 30 Niethammer A G, Forman E N. Use of the platelet histogram maximum in evaluating thrombocytopenia.  Am J Hematol . 1999;  60 19-23
• 31 Saxon B R, Moody M, Blanchette V S, Freedman J. Reticulated platelet counts in the assessment of thrombocytopenic disorders.  Acta Paediatr . 1998;  424 65-70
• 32 Kenet G, Lubetsky A, Shenkman I. Cone and platelet analyser (CPA): a new test for the prediction of bleeding among thrombocytopenic patients.  Br J Haematol . 1998;  101 255-259
• 33 Fressinaud E, Veyradier A, Truchaud F. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases.  Blood . 1998;  91 1325-1331
• 34 Carcao M D, Zipursky A, Butchart S, Leaker M, Blanchette V S. Short-course oral prednisone therapy in children presenting with acute immune thrombocytopenic purpura (ITP).  Acta Paediatr . 1998;  424 71-74
• 35 Crosby W H. Wet purpura, dry purpura.  JAMA . 1975;  232 744-745
• 36 Palareti G, Leali N, Coccheri S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT).  Lancet . 1996;  348 423-428
• 37 van der Meer J M F, Rosendaal F R, Vandenbroucke J P, Briët E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants.  Thromb Haemost . 1996;  76 12-16
• 38 Katsanis E, Luke K-H, Hsu E, Li M, Lillicrap D. Prevalence and significance of mild bleeding disorders in children with recurrent epistaxis.  J Pediatr . 1988;  113 73-76
• 39 Buchanan G R, Holtkamp C A. Prednisone therapy for children with newly diagnosed idiopathic thrombocytopenic purpura.  Am J Pediatr Hematol Oncol . 1984;  6 355-361
• 40 Buchanan G R, Daigle C. Bleeding severity assessment in patients with idiopathic thrombocytopenic purpura (Abst).  J Pediatr Hematol Oncol . 2000;  22 372
• 41 Kattamis A C, Shankar S, Cohen A R. Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenously administered immunoglobulin G.  J Pediatr . 1997;  130 281-283
• 42 Gaines A R. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh₀(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients.  Blood . 2000;  95 2523-2529
• 43 Landgraf J M, Abetz L N. Functional status and well-being of children representing three cultural groups: initial self-reports using the CHQ-CF87.  Psychol Health . 1997;  12 839-854
• 44 Waters E, Wright M, Wake M, Landgraf J M, Salmon L. Measuring the health and well being of children and adolescents: a preliminary comparative evaluation of the Child Health Questionnaire (CHQ-PF50).  Ambulatory Child Health . 1999;  5 131-141
• 45 Tamminga R YJ, Poortman G H, Kamps W A. Psychosocial impact of chronic idiopathic thrombocytopenic purpura: a parent's view.  Int J Pediatr Hematol Oncol . 1999;  6 255-260
• 46 Barnard D R, Blanchette V S, David M. Phase I development of a disease specific health related quality of life (HRQoL) instrument for use in children with immune thrombocytopenia (ITP) (Abst).  J Pediatr Hematol Oncol . 1998;  20 373
• 47 Barnard D R, Blanchette F S, David M. The burden of childhood ITP.  Int J Pediatr Hematol Oncol . 2000;  7 13-15
• 48 Buchanan G R, Daigle C, Horan C P. Bleeding severity, side effects, and quality of life in children with idiopathic thrombocytopenic purpura (ITP) (Abst).  J Pediatr Hematol Oncol . 2000;  22 373
• 49 Sandler S G, Novak S C, Roland B. The cost of treating immune thrombocytopenic purpura using intravenous Rh immune globulin versus intravenous immune globulin.  Am J Hematol . 2000;  63 156-158
• 50 Hollenberg J P, Subak L L, Ferry Jr J J, Bussell J B. Cost-effectiveness of splenectomy versus intravenous gamma globulin in treatment of chronic immune thrombocytopenic purpura in childhood.  J Pediatr . 1988;  112 530-539
• 51 Earle C, Chapman R H, Baker C S. Systematic overview of cost-utility assessments in oncology.  J Clin Oncol . 2000;  18 3302-3317
• 52 Meyerson L J, Wiens B L, LaVange L M, Koutsoukos A D. Quality control of oncology clinical trials.  Hematol Oncol Clin North Am . 2000;  14 953-971